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ABSTRACT 
Reactive oxygen species, ROS, are beneficially involved in many signaling 
pathways that control development and maintain cellular homeostasis. In 
physiological conditions, a tightly regulated redox balance protects cells from 
injurious ROS activity, but if the balance is altered, it promotes various pathological 
conditions including cancer. Understanding the duality of ROS as cytotoxic 
molecules and key mediators in signaling cascades may provide novel 
opportunities for improved cancer therapy. 
 
MAP17 is a small 17-kDa non-glycosylated membrane protein that is overexpressed 
in many tumors of different origins, including carcinomas. Immunohistochemical 
analysis of MAP17 during cancer progression demonstrates that overexpression of 
the protein strongly correlates with the progression of most types of tumor. Tumor 
cells that overexpress MAP17 show an increased tumoral phenotype associated 
with an increase in ROS. However, in non-tumor cells MAP17 increases ROS, 
resulting in senescence or apoptosis. Therefore, in tumor cells, MAP17 could be a 
marker for increased oxidative stress and could define new therapeutic 
approaches. Here, we review the role of MAP17 as a putative oncogene, as well 
as its role in cancer and anticancer therapy. 
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1. An Introduction to ROS 
ROS may promote either proliferation or cell death, depending on the 
intensity and location of the oxidative burst and the activity of the antioxidant 
system [1, 2]. Considering the proliferation signals delivered by ROS to cancer cells, 
and the consequent resistance of cancer cells to pro-apoptotic signals, ROS-
induced tumor cell death is likely to be induced by ROS-generating antineoplastic 
therapies that increase the constitutive oxidative stress above the critical threshold 
required for cell death. 
Cancer cells develop an enhanced constitutive oxidative stress that sustains 
tumor growth and protects these cells against proapoptotic signals, thus 
promoting tumor progression [1, 3]. In experimental models, it has been shown that 
ROS generation in tumors and the subsequent oxidative stress actually occur at 
sublethal levels [4].  However, many therapeutic drugs, as well as radiotherapy 
and photodynamic therapy, kill cancer cells, at least in part by increasing ROS  [1, 
5, 6] . 
Evidence exists that the role of ROS in cancer is not limited to the generally 
accepted genotoxic and mutagenic effects that initiate cancer. As signal 
transduction messengers, ROS may promote the proliferation, senescence or 
death of cancer cells, depending on the actual intracellular and exogenous 
conditions. ROS have been shown to modulate growth signals and to activate 
expression leading to the sustained proliferation of cancer cells [3, 7]. An emerging 
view is that upon oncogenic transformation, cells rapidly activate a stress response 
as a protective measure to overcome oncogene-induced cell death and 
senescence [8]. Cancer cells subject to persistent endogenous and exogenous 
oxidative stress were shown to develop adaptive responses primarily related to the 
upregulation of the antioxidant machinery. Therefore, cancer cells might become 
resistant to both enhanced constitutive stress and ROS-generating therapies, 
limiting the efficacy of the latter. 
 
Current “ROS threshold” theories suggest that along with increases in ROS, 
cell responses change from proliferation to balance and then to cell death after 
ROS surpass a certain level [9]. Therefore, normal cells differ from tumor cells in their 
ability to control redox homeostasis. In normal cells, the use of antioxidants to 
scavenge free radicals protects from ROS-induced malignant transformation. In 
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tumors, antioxidant or low levels of ROS that induce antioxidant defenses appear 
to benefit tumor growth and could enhance anticancer therapy resistance [9]. 
However, redox loading of tumor cells increases ROS to close to threshold levels. 
Then, when both normal and tumor cells are exposed to ROS-inducing therapies, 
the ROS levels in tumor cells will more easily reach levels that cause cell death [6]. 
This theory indicates that modest increases of ROS are oncogenic, while high ROS 
levels suppress tumors. 
 
Accumulating evidence implicates ROS in signaling cascades related to cell 
proliferation and transformation [4, 10, 11]. Ras-transformed fibroblasts 
overproduce ROS, and this overproduction is correlated with the activation of 
mitogenic signaling pathways [10]. Loss of superoxide-dismutase, MnSOD, which 
should elevate ROS levels, has also been correlated with a tumoral phenotype, 
and overexpression of MnSOD leads to the reversion of the transformed 
phenotype [12-15]. On the other hand, H2O2 is generated in response to the 
growth factors EGF and PDGF and is linked to growth-related signaling [11, 16]. 
When overexpressed in NIH 3T3 mouse fibroblasts, Nox1, an NADPH oxidase 
catalytic subunit, induces excessive production of ROS and a transformed 
phenotype with increased mitotic rates and aggressive tumor formation in athymic 
mice [17]. The phenotype of Nox1-transfected cells can be reversed by ROS 
reduction through stable expression of catalase, thereby implicating ROS as a 
signaling molecule [17]. Although later experiments do not support that claim [18, 
19], high levels of Nox1 with increased levels of ROS have been detected in colon 
and prostate samples [18-22]. Nox4 was shown to sustain prostate cancer cell 
survival after activation by signals provided by the extracellular matrix [23]. On the 
other hand, decreased activity of antioxidants has been observed in ovarian 
cancer patients [24]. Decreased expression and activity of mitochondrial MnSOD 
have been reported in colorectal and pancreatic carcinomas correlated with 
altered redox status [25, 26]. Furthermore, various oncogenic signals such as those 
induced by oncogenic Raf, c-myc or Bcr-Abl were shown to be involved in 
increasing ROS generation via the NADPH oxidase pathway [27, 28]. 
  The cellular targets responsible for growth and transformation affected by 
ROS signaling are not well known. The p42/p44 mitogen-activated protein kinase 
(MAPK), p38 MAPK, p70S6k, signal transducers and activators of transcription 
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(STAT), Akt/Protein Kinase B and phospholipase D signaling pathways are all 
activated by reactive oxygen species [16, 29-31]; however, in some cases, 
activation is indirect [32, 33]. A direct effect has been shown for protein tyrosine 
phosphatase-1B (PTP-1B), which is inhibited by oxidation of a thiol in the active site 
[34, 35] leading to increased phosphotyrosines on many cell proteins. Furthermore, 
ROS increase activates the PI3K pathway by direct oxidation and inactivation of 
PTEN and other AKT phosphatases, thus maintaining AKT activation even in the 
absence of a PI3K signal [36]. A variety of other targets can also be affected by 
ROS, including transcription factors such as NF-kB [37], activator protein-1 (AP1) 
[38], PTEN [39] and p53 [40]. ROS can directly modify signaling proteins through 
different modifications such as nitrosylation, carbonylation, disulfide bond 
formation and glutathionylation [41]. Whatever the proximal target(s), ROS can 
reprogram the expression of enzymes and other proteins in the cell [42, 43]. DNA 
microarray experiments [17] indicate that up to 2% of the genes are 
transcriptionally regulated by ROS.  
 
2. MAP17 is overexpressed in cancer 
Functional genetic screens using retroviral delivery of high complexity cDNA 
libraries are valuable tools to discover new genes involved in a particular 
phenotypic characteristic of the tumorigenic process [44-46]. A genome-wide 
retroviral cDNA screen to search for genes that confer a selective advantage to 
cancer cells during tumorigenesis allowed us to identify MAP17 [47]. MAP17 is a 
small, non-glycosylated, membrane-associated 17-kDa protein that localizes to 
the plasma membrane and the Golgi apparatus [48]. The protein sequence 
contains two transmembrane regions and a hydrophobic amino-terminus of 13 
amino acids encoding a PDZ-binding domain [49]. MAP17 overexpression in 
carcinomas was first detected by using the technique of differential display [50]. 
Transfection of full-length wild-type MAP17 into HT29 colon carcinoma cells 
decreased cell proliferation in vitro and tumor growth in vivo [51]. MAP17 binds 
several PDZ domain-containing proteins, including PDZK1, NHERF1, NaPi-IIa and 
NHe3. Overexpression of MAP17 in opossum kidney cells participates, together with 
PDZK1 and NH3RF4, in NaPi-IIa internalization to the trans-Golgi network [52]. The 
physiological role of MAP17 in proximal tubules is not well known, but it does 
stimulate specific Na-dependent transport of mannose and glucose in Xenopus 
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oocytes [48] and human tumor cells [47]. The MAP17 gene shares regulatory 
elements with the stem cell leukemia gene (SCL, TAL-1), which encodes a basic 
Helix-Loop-Helix protein essential in the formation of the hematopoietic lineages 
[53, 54].  However, in non-cancerous tissues, major expression of MAP17 has only 
been detected in kidney cells.  
 
In a meta-analysis of public microarray databases for different skin diseases, 
Noh et al. [55] discovered that MAP17 is commonly upregulated, suggesting that it 
may be associated with abnormal keratinocyte differentiation. MAP17 was 
significantly upregulated in response to interferon-gamma, interleukin 4 (IL-4), IL-6, 
IL-17A or IL-22 in normal human epidermal keratinocytes. Interestingly, the PDZK1 
gene is localized within the atopic dermatitis-linked region on human chromosome 
1q21. In an attempt to evaluate whether MAP17 regulates the expression of 
cornified envelope-associated genes at the 1q21 locus, such as filaggrin, loricrin 
and involucrin, these authors [55] found that the over-expression of MAP17 in 
HaCaT keratinocytes significantly decreased the expression of filaggrin, a cornified 
envelope-associated gene. Taken together, the Th cell cytokine-induced 
upregulation of MAP17 expression may be linked to the downregulation of 
filaggrin, which may be associated with the abnormal epidermal differentiation 
observed in the dermatological diseases [55]. 
 
Human MAP17 maps to chromosome 1p33, a locus commonly found to be 
involved in cancer; however, it is not the only interesting gene in this region. Genes 
coding for members of the cytochrome P450 family (CYP4B1, CYP4A11), putative 
oncogenes (SCL/Tal1), MCPH7, CMPK1, and members of the forkhead family 
(FOXE3, FOXD2) are its neighbors.  
 
MAP17 overexpression has previously been shown to be associated with 
carcinomas [50, 51]. An in-depth analysis of MAP17 overexpression in carcinomas 
by immunohistochemistry and mRNA expression showed that the MAP17 protein is 
overexpressed in a large percentage of the tumors analyzed (Figure 1) and is 
significantly correlated with the tumor grade at least in ovarian, breast and 
prostate carcinomas [56]. A comparison of tumoral with non-tumoral tissues of the 
same patient by hybridization or by analyzing mRNA levels by Q-PCR 
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demonstrated an even higher percentage of tumor samples with MAP17 
overexpression [56]. Overexpression was observed in more than 70% of the 
samples from tumors such as ovary, colon, stomach, cervix and thyroid and in 
approximately 50% of the samples from tumors of the lung, uterus and rectum. 
Although more samples need to be analyzed to confirm these high frequencies, 
the data suggest that MAP17 overexpression is the most common marker of 
tumorigenesis in carcinomas. The relevance of MAP17 as a general marker for the 
malignant stages of human tumors still needs to be confirmed in additional tumor 
types and larger cohorts. Furthermore, MAP17 expression seems to correlate with 
AKT473 phosphorylation and p38 T180/Y182 dephosphorylation [57].  
 
MAP17 overexpression in carcinomas occurs mostly through mRNA 
amplification (Figure 2). MAP17 overexpression could be due to the ability of the 
MAP17 promoter to be activated by oncogenes [50, 56]. Tumorigenic progression 
involves progressive genetic alterations triggering oncogenic cascades [58]. In 
advanced stages, tumors might accumulate oncogenic alterations that result in a 
high probability of MAP17 promoter activation and increased transcription. This 
hypothesis could explain the correlation between the MAP17 overexpression and 
advanced tumor stages observed in many tumor types. 
 
However, the preceding data do not provide an explanation of why MAP17 
overexpression provides a selective advantage during tumorigenesis. Multiple 
oncogenes that activate signaling pathways directly involved in cell survival or 
proliferation have been discovered in previous decades. Other genes may 
provide an advantage to the tumoral cells, making them insensitive to 
physiological signals or altering their normal physiology. Although activated 
macrophages destroy cancer cells more effectively than normal cells, the ability 
to escape activated macrophages is a characteristic of tumor cells. One of the 
mechanisms responsible for the specific killing of tumor cells by macrophages is 
the production of the cytokine tumor necrosis factor alpha (TNF). Therefore, 
resistance to TNF may provide cancer cells with a selective advantage against 
host elimination. Ectopic expression of MAP17 in tumor cells prevents TNF-induced 
G1 arrest by impairing p21waf1 induction. However, expression of MAP17 does not 
inhibit TNF-induced apoptosis in Me180-sensitive tumor cells. The inhibition of TNF is 
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specific because MAP17 does not alter the response to other cytokines, such as 
IFNa. As described in the Xenopus oocyte system, MAP17 increases the uptake of 
mannose in some cells, but this effect is not responsible for TNF bypass [47]. 
 
3. MAP17 expression enhances the tumorigenic phenotype by increasing 
intracellular ROS  
Tumor cells that overexpress MAP17 show an increased tumoral phenotype 
with enhanced proliferative capabilities, both in the presence and absence of 
contact inhibition, decreased apoptotic sensitivity and increased migration [59]. 
MAP17-expressing clones also grow better in nude mice. The increased malignant 
cell behavior induced by MAP17 is associated with an increase in ROS production, 
and the treatment of MAP17-expressing cells with antioxidants results in a 
reduction in the tumorigenic properties of these cells. The MAP17-dependent 
increase in ROS and tumorigenesis is dependent on its PDZ-binding domain 
because disruption of this sequence by point mutations abolishes the ability of 
MAP17 to enhance ROS production and tumorigenesis [57, 59].  
 
MAP17 also decreases the c-Myc-induced caspase-3-like activity in Rat1 
fibroblasts under low serum conditions. This decrease is in keeping with the 
concept of MAP17-induced PI3K/AKT signaling, in which MAP17 is able to interfere 
with Bax translocation to the mitochondria [36]. A fraction of PTEN protein is 
oxidized in MAP17-overexpressing cells. Furthermore, activation of AKT by MAP17 
as measured by Thr308 phosphorylation is independent of PI3K activity. 
Importantly, modulation of ROS by antioxidant treatment prevented activation of 
AKT, thus restoring the level of apoptosis in serum starved Rat1/c-Myc fibroblasts 
[36]. Therefore, overexpression of MAP17 protects Rat1a fibroblasts from Myc-
induced apoptosis through ROS–mediated activation of the PI3K/AKT signaling 
pathway [36].  
 
 The increased tumorigenic properties induced by MAP17 are associated 
with an increase in ROS because MAP17 increases endogenous ROS, and 
antioxidant treatment of MAP17-expressing cells entails a reduction in the 
tumorigenic properties of these cells. Two explanations can be offered for the 
mechanism by which ROS induce the transformed phenotype. First, reactive 
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oxygen generated in the presence of MAP17 may be mutagenic, causing the 
transformed phenotype through the induction of mutations in oncogenes or tumor 
suppressor genes. Alternatively, ROS generated in a MAP17-dependent manner 
might function as an intracellular signal, inducing a growth-related genetic 
program. ROS removal by antioxidant treatments decreases the malignant cell 
behavior induced by MAP17; thus, the second hypothesis is favored. Furthermore, 
in breast carcinoma cells, elimination of ectopically expressed MAP17 reduced 
the tumorigenic capabilities [57]. This reversibility of the phenotype indicates that 
the effect induced by MAP17 is largely independent of ROS-induced DNA-
mutations. 
 
However, the increased tumoral properties of carcinoma cells were not 
paralleled in naïve non-tumoral cells [57], indicating that MAP17 provides a 
selective advantage once tumorigenesis has begun. Our data demonstrate that 
ROS act as a second messenger that enhances tumoral properties but only in 
those cells where the senescence/apoptotic signal provided by ROS is uncoupled. 
We have found that p38a activation at least partly mediates this response. MAP17 
triggers a ROS-dependent, senescence-like response that is abolished in the 
absence of p38a activation. Furthermore, in human breast tumors, MAP17 
activation is correlated with lack of p38a phosphorylation. Therefore, MAP17 is 
overexpressed in late-stage breast tumors, in which oncogenic activity relies on 
p38 insensitivity to induced intracellular ROS [57]. 
 
4. ROS increase 
 How are ROS increased by MAP17? One possibility is that MAP17 can 
increase glucose and mannose uptake, inducing an increase in metabolism with 
ROS as side products. However, it is also possible that a direct link with the 
membrane transporters ends, altering the intracellular redox balance by altering 
the intra/extracellular ion balance. 
 The structural simplicity of MAP17 and the kinetic analysis of the induced 
membrane transport [60] suggest that MAP17 is an activator of the capacity of 
endogenous uphill transporters. MAP17 could modulate the activity or the 
organization of membrane transporters through direct interaction as the RS1 
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modifier does [61] or through competition for PDZ-binding domains to alter the 
stoichiometry of the transporter-PDZ proteins [60].  
 
4.1. MAP17 binding to PDZK1 (NHeRF3, CAP70, NaPi-Capl and CLAM)  
Kocher et al. [62] first described the interaction between MAP17 and 
PDZK1 detected by using a two-hybrid system. In a transgenic mouse model, 
MAP17 hepatic overexpression resulted in a liver deficiency of PDZK1, suggesting 
that MAP17 is an endogenous regulator of PDZK1 turnover [63]. MAP17 acts as an 
atypical anchoring site for PDZK1 and interacts with the NaPi-IIa/PDZK1 protein 
complex in renal proximal tubular cells [64].  
PDZK1 belongs to the NHeRF (sodium hydrogen exchange regulatory 
factor) family, members of which are PDZ domain-containing proteins that play 
important roles in regulating cell function [65]. This family contains four members, 
NHeRF1, NHeRF2, PDZK1 and IKEPP (NHeRF4), that share similar homology domains 
[65]. NHeRF1and NHeRF2 each contain 2 PDZ domains, while PDZK1 and IKEPP 
each contain 4 PDZ domains [66]. NHeRF1 was initially identified as a membrane-
associated protein that is essential for the regulation of the PKA-induced inhibition 
of the Na-H exchange isoform 3 (NHe3). NHeRF2 was also identified as a mediator 
of NHe3 inhibition by cAMP. Although the different members of the family carry 
some overlapping functions, it is clear that there is a significant amount of 
specificity among them [67]. Thus, PDZK1 is a typical scaffolding protein defined by 
the presence of globular PDZ domains that assemble several proteins into 
functional complexes. PDZK1 is a critical spatio-temporal regulator of intracellular 
signaling in response to specific stimuli [68]. MAP17 has been shown to interact 
with PDZK1 and NHeRF1 [69] (Figure 3A). 
The NHeRF proteins are primarily expressed in the polarized epithelial cells at 
the apical side. Kidney, small intestine and liver tissues exhibit the highest 
expression levels of these proteins [70, 71]. 
The NHeRF proteins regulate cell surface expression and functional activity 
of transporters. Most transporters identified as binding partners belong to the ABC 
family [66]. In addition to transporters, other proteins have been shown to interact 
with NHeRF proteins, including signaling proteins, hormone receptors and 
cytoskeleton structural elements [65, 72]. Many proteins related to the G-protein 
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signaling pathways were found to interact with PDZK1, and they were likely to be 
functionally associated with transporters.  
PDZK1 forms heterooligomers with NHeRF1 in vitro, which may allow the 
formation of an entire network of PDZ adapter proteins underneath the plasma 
membrane [73]. 
MAP17 complexes with PDZK1 and NHe3 contributing to basal and calcium 
inhibition of NH3 activity [74]. PDZK1 also regulates the solute carriers SLC15a1 
(oligopeptide transporter, PEPT1) and SLC22a5 (carnitine/organic cation 
transporter, OCTN2) in the small intestine [75], the cystic fibrosis transmembrane 
conductance regulator (CFTR) and the anion exchangers of the SLC26A family, 
leading to its stabilization [76]. PDZK1 has also been shown to interact with AKAP10, 
FARP2, sodium-hydrogen antiporter 3 regulator 1, SLC22A12, SLK, SLC22A4 [77], 
CLCN3, cystic fibrosis transmembrane conductance regulator [78] and SLC34A3 
[77]. Coupling CFTR to DRA and PAT1 results in activation of the Cl-/HCO3- 
exchange. As a consequence of transport regulation, binding of MAP17 to NHeRF 
proteins might result in the deregulation of the intracellular and extracellular 
cation/anion balance, causing increased nonenzymatic oxidative stress in the 
cells. 
On the other hand, PDZK1 interacts with CMOAT, a canalicular multispecific 
organic anion transporter involved in multidrug resistance. This finding was 
considered of particular interest because proteins containing PDZ domains are 
involved in the clustering and signaling pathways of membrane-associated 
proteins, including ion channels. Therefore, the protein cluster formed by the 
association of CMOAT, PDZK1, and MAP17 could play an important role in the 
cellular mechanisms associated with multidrug resistance, and PDZK1 may 
represent a new target in cancer cells resistant to chemotherapeutic agents. In 
line with this argument, the overexpression of PDZK1 within the 1q12-q22 amplicon 
is likely to be associated with the drug resistance phenotype in multiple myeloma 
[79]. 
 
4.2. SGLTs and Gluts transporters 
The Na-dependent glucose transporter 1 (SGLT1, SCL5A1) is the main 
mediator of apical glucose uptake, whereas at the basolateral membrane the 
glucose transporter GLUT1 facilitates diffusive transport of intracellular glucose into 
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the bloodstream [80]. SGLT1 mRNA is present mainly in the intestine and kidney [81, 
82]. Located at 22q13.1, SGLT1 is responsible for active glucose absorption, which 
is an energy requiring action driven by the Na+/K+ ATPase [83]. 
MAP17 binds and activates specific Na-dependent transport of mannose 
and glucose in Xenopus oocytes [48]. The induced transport has the functional 
characteristics of the Na-glucose cotransporters, the SGLTs [60]. Ectopic expression 
of MAP17 in human cells, tumoral or not, triggers increased absorption of glucose 
and mannose [47]. This transport is inhibited by phloridzin, suggesting that the 
increase is due to the SGLT1 transporter, corroborating the previous finding in 
Xenopus [47]. We have also found that MAP17 and SGLT1 colocalize in some 
tumors (Data not shown).  
 
Previous studies demonstrated that activation of SGLT1 rescued enterocytes 
from apoptosis by activating PI3K [84] and that inhibition of this membrane 
transport with phloridzin also inhibited MAP17-dependent ROS increase and 
proliferation [59]. Together, these results suggest that MAP17-dependent 
tumorigenic properties may depend upon the activation of ROS by SGLT1 
membrane transport. SGLT1, on the other hand, has been previously related to 
cancer [85], showing correlation with prognosis. Furthermore, silencing EGFR 
decreases SGLT1 significantly reducing the intracellular concentrations of glucose 
[86]. Despite what seems a clear functional relationship, no direct evidence for 
binding of MAP17 to SGLT1 in mammalian cells has been published. 
 
In normal cells under aerobic conditions, the oxidation of glucose involves 
cytoplasmic glycolysis and oxidative phosphorylation by the mitochondrial 
electron transport chain, which produces a maximum of ATP by completely 
oxydizing glucose to CO2. Under hypoxic conditions, normal cells perform 
anaerobic glycolysis because mitochondrial function is suppressed in the absence 
of O2. Anaerobic glycolysis generates lactate from pyruvate, which is the only way 
to regenerate NAD+, the coenzyme for glyceraldehyde 3-phosphate 
dehydrogenase. Despite the low energy produced in anaerobic glycolysis (16 fold 
lower than oxidative phosphorylation), tumor cells largely rely on the conversion of 
glucose to lactate rather than on mitochondrial oxidation for energy production 
 13 
even in the presence of high oxygen levels [87-91]. This effect is known as the 
Warburg effect, or aerobic glycolysis [92, 93]. 
Tumor cells, therefore, have mostly inhibited oxidative phosphorylation, 
reducing ATP production. They do not allow electrons to go through the electron 
transport chain all the way to oxygen, thus increasing the generation of ROS [93-
95]. 
Thus, reduced ATP generation in mitochondria is a compromise that tumor 
cells make to initiate oncogenic transformation. Tumor cells must increase their 
access to glucose to support the high rate of glycolysis. This is achieved by an 
increased transport of glucose into the cells. The rate of glucose entry into tumor 
cells is at least 20- to 30-fold higher than in normal cells [91]. Tumor cells enhance 
glucose uptake via the induction of Glut1 and SGLT1, and coordinate the 
increased entry of glucose with increased glycolysis [91, 96, 97].  
 
Pyruvate, but not lactate, is an effective inhibitor of histone deacetylases 
[98, 99]. Therefore, accumulation of pyruvate in tumor cells can potentially kill 
them, and aerobic glycolysis must be maintained to eliminate pyruvate and 
produce the lactate that will be used for essential NAD+ production. 
On the other hand, an increased level of lactate in the cytoplasm will 
decrease cellular pH, potentially compromising survival. Tumor cells employ many 
mechanisms to prevent cellular acidification [100]. Cellular acidification results 
from enhanced glucose uptake and anaerobic metabolism by tumor cells. This 
acidic intracellular pH can be exacerbated by inefficient removal of lactic acid, 
CO2 and H+ by deficient vasculature in the tumor [101]. Since small variations in 
the intracellular pH alter many biological functions such as membrane 
permeability, enzymatic activity, ATP maintenance and production, proliferation, 
migration, invasion, metastasis or drug resistance and apoptosis, the cells must 
regulate the intracellular pH to survive. The hypoxia inducible factor, HIF1, 
regulates under hypoxic conditions anaerobic glycolysis and pH homeostasis by 
enhancing both, the expression of glycolytic enzymes and the membrane located 
transporters, exchangers and ecto-enzymes [102]. The system regulating the 
intracellular pH in tumor cells actively export acids via the NHe1 exchanger [103-
105], the monocarboxilate transporters (MCTs) [106], and, to induce cytoplasmatic 
alkalinization, transports HCO3- into the cells through Cl-/HCO3- exchangers and  
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Na+/HCO3- cotransports [107]. The NHe1 is also enhanced in many tumors 
pumping H+ out of the cells coupled to a transmembrane gradient. Additionally, 
H+/lactate-coupled transporters, carbonic anhydrases, could facilitate H+ efflux, 
preventing acidification of the cytoplasm [108].  
Most of these membrane transporters could be regulated by MAP17 levels 
and localization through NHeRF proteins binding (Figure 3B). Therefore, the 
MAP17/NHeRF complexes could be an intracellular pH/acidosis detoxifying system 
parallel to carbonic anhydrases. It is possible that MAP17/NHeRFs-dependent 
system be also induced under hypoxic conditions maintained through further 
malignization. However, the fact that levels of MAP17 rise with the stage of the 
tumor suggests that may be more related to continuous selection of cells with 
higher pH detox capabilities. Further experimental validation is necessary to clarify 
these hypotheses. 
By activating MAP17, cells will insure increased membrane localization of 
internal pH detoxifying transporters. Several oncogenes could activate MAP17 
expression [56] promoting MAP17 increase along with increased metabolism. 
Unspecific membrane transporter inhibitors, such as furosemide, produce similar 
effects on cellular proliferation than phloridzin, an SGLT inhibitor, suggesting the 
functional relationship between SGLT and the pH regulation [59]. Thus, enhanced 
membrane transport to prevent acidification may be regulated by MAP17 through 
NHeRF binding allowing SGLT1 increase and anerobic glycolysis activation in tumor 
cells. 
 
However, it is also possible that secondary effects of an increase in glucose 
and mannose, such as glycosylation and mannosylation of proteins might alter 
properties of the cells, including oxidative stress or tumorigenic properties, thus 
contributing to the MAP17-induced tumoral phenotype. 
 
5. MAP17 and cancer therapy 
Treatment of melanoma cells with inhibitors of Na+-coupled cotransporters 
leads to an inhibition of a ROS increase and a decrease in the malignant cell 
behavior in MAP17-expressing clones [59]. These changes could result in a new 
therapeutic approach by nonspecifically blocking uphill transport in tumor cells. 
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However, the rapid adaptation of the cells to these pharmacologic interventions 
and possible toxic effects need to be better studied. 
 
A low level of ROS is indispensable in several physiological processes of the 
cell, including proliferation and apoptosis, or cell death [109]. A mild increase in 
ROS has been shown to activate signaling cascades which can seriously influence 
the regulation of cell growth and tumorigenic processes [4, 10, 11, 16, 31, 42, 43, 
57, 110]. However, a further increase in ROS levels raises oxidative stress and 
creates a potentially toxic environment for the cell. In normal physiological 
conditions, a balance between ROS generation and oxidative defenses exists in 
the cell. In these defenses, endogenous antioxidant enzymes play a significant 
role. Superoxide dismutase (SOD) and catalase (CAT) that act on O2- and H2O2, 
respectively, glutarredoxins, glutathione peroxidases (GPXs) that use glutathione 
as a cosubstrate, peroxiredoxins and thioredoxins, are in a delicate balance with 
oxidative inputs [1, 110]. Although many cells can tolerate limited doses of ROS, 
when the balance tips further in favor of ROS, programmed cell death becomes a 
certainty [111]. Cellular detoxification enzymes cannot neutralize excessive ROS 
that alter the chemical environment in the cells, especially within the 
mitochondria, and launch the cell death program. 
Therefore, we can hypothesize that tumors expressing high levels of MAP17 
and producing ROS can benefit from therapies that increase oxidative stress, such 
as cisplatin and radiotherapy, doxorubicin or camptothecin, which have redox-
mediated activity [112] on tumor cells without affecting healthy tissues [113]. 
Tumors with high MAP17 can also benefit from combined therapies using cytotoxic 
agents and increased oxidative stress. The first attempt to employ pro-oxidant 
agents in vivo was reported by Nathan and Cohn in 1981. Using glucose oxidase 
as an H2O2 precursor, they obtained a significant decrease of tumor growth [114, 
115]. 
Because cells can develop adaptive responses to ROS, primarily based on 
the increase of detoxifying enzymes [8], we can hypothesize that the inhibition of 
classical oxidative stress detoxifying enzymes can also increase the efficacy of 
certain antitumor therapies that increase ROS, at least in tumors that overexpress 
MAP17. However, the delicate balance between oxidative stress, cancer and cell 
 16 
death make it necessary to devise new experimental tests and develop a more 
complete understanding of these processes. 
 
6. CONCLUSIONS 
In summary, the observation that MAP17 is overexpressed in human 
carcinomas indicates that MAP17 can be a good marker for tumorigenesis and for 
malignant progression. The results indicate that this protein is likely to play an 
important role in carcinogenesis and likely in the response to certain therapies 
related to oxidative stress. On the other hand, the overexpression of PDZK1 within 
the 1q12-q22 amplicon is likely to be associated with the drug resistance 
phenotype in multiple myeloma [79]. All of these data suggest that the uphill 
transport and SGLT1-dependent glucose uptake might be important players in the 
correct balance of ROS in cells, indirectly regulating the ability to select more 
aggressive tumor cell populations. Therefore, a deeper understanding of this 
system might be of interest to the cancer field. 
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Figure legend 
 
Figure 1: Representative pictures of human tumors overexpressing MAP17. A) 
Colorectal carcinoma. B) Undifferentiated cervical carcinoma. C) Mammary 
carcinoma. D) Lung adenocarcinoma. Pictures show tumor cells, characterized by 
nuclear displasia, heavily stained for MAP17 expression. Non tumoral cells forming 
the stroma, show no staining.  
 
Figure 2: Overexpression of MAP17 in human tumors. Graphs show overexpression 
of MAP17 mRNA in tumors compared with non-tumoral tissue in a large-scale 
microarray data set from different studies (www.oncomine.com). A) From [116]. B) 
From [117]. C) From [118]. D) From [119]. E) From [120]. F) From [120]. 
 
Figure 3: A) Scheme of the possible functional role of MAP17 as an anchor for 
PDZK1-membrane transporter complexes. B) Scheme of hypothetic functional 
relationship between SGLT1 and MAP17 through NHeRF. SGLT1 increase in tumor 
cells to respond to high glucose demand, while MAP17 increase to regulate the 
subsequent intracellular acidification through NHeRF binding and localizing pH 
detoxifying enzymes in the membrane. 
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Abbreviations 
PDZ, Post-synaptic density 95, Disc large, Zonula occludens 1 
PDZK1, PDZ domain-containing 1 
CLAMP, c-terminal linking and modulating protein;  
CAP70, CFTR-associated protein, 70-KD 
MAP17, Membrane associated protein 17 KD 
NHeRF, Na+/H+ exchanger regulatory factor 
IKEPP, Intestinal and kidney enriched PDZ protein 
SGLT, Na+/glucose cotransporter  
 
 
